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Abstract Introduction: Practice effects are characteristic of nearly all standard cognitive tasks when repeated
during serial assessments and are frequently important confounders in clinical trials.
Methods: We summarize evidence that gains in neuropsychological test performance scores associ-
ated with practice effects occur as artifactual changes associated with serial testing within clinical
trials. We identify and emphasize such gains in older, non–cognitively impaired individuals and es-
timate an effect size of 0.25 for composite cognitive measures in older populations assessed three
times in a 6- to 12-month period.
Results: We identified three complementary approaches that can be used to attenuate practice ef-
fects: (1) massed practice in a prebaseline period to reduce task familiarity effects; (2) tests designed
to reduce practice-related gains so that item-specific driven improvements are minimized by using
tasks that minimize strategy and/or maximize interitem interference; and (3) well-matched alternate
forms.
Discussion: We have drawn attention to and increased awareness of practice effect–related gains that
could result in type 1 or type 2 errors in trials. Successfully managing practice effects will eliminate a
large source of error and reduce the likelihood of misinterpretation of clinical trials outcomes.
 2015 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Practice effects are characteristic of serial neurocognitive
assessments, including those used in clinical trials. They
refer to changes in test performance attributed to increasing
familiarity with and exposure to test instruments, paradigms,
and items. Nevertheless, these effects are often underappre-
ciated. Our own work in this area [1–3] has identified them
as important in the interpretation of both outcomes in
clinical trials and in longitudinal studies of patients with
schizophrenia. Here, we discuss the relevance of these
findings to clinical trials for Alzheimer’s disease (AD) and
mild cognitive impairment (MCI), a stage often thought to
be transitional between cognitive health and AD, and,
notably, preclinical AD [4]. Preclinical AD at stages 1 and
2 refers to those individuals who have cerebrospinal fluid
or positron emission tomography evidence of amyloid-b ab-
normalities and/or “downstream” neurodegeneration but do
not demonstrate cognitive changes; at stage 3, individuals
additionally suffer from subtle cognitive changes. For pre-
clinical AD, the assessment of cognition has been suggested
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by the Food and Drug Administration (FDA) as a suitable
and sole primary end point for the accelerated approval of
a pharmaceutical treatment (FDA Draft Guidelines for Early
Stage AD) [5]. For recent clinical trials in AD and MCI,
studies typically used designs comparing cognition between
the drug and placebo groups, assessed on several occasions
but within a relatively short period of 18 months to 2 years,
and with the end point or final assessment used as the
outcome. That end point, however, may be strongly influ-
enced by previous testing as we show in Sections 3 and 7
below. Thus, the serial testing used in these clinical trials
may result in unappreciated but artifactual gains across a
range of neuropsychological measures, including speed of
processing, episodic memory, executive function, and
working memory.
Practice effects may result from several different factors
and in our view can be divided into two components. The
first can be termed task familiarity and occurs early in serial
assessment with given cognitive tasks. It involves the subject
gaining full comprehension of the directions for the task
necessary for context memory (e.g., that letters and numbers
alternate in Trail-Making Test B), some knowledge of the
sequence of a task (e.g., that multiple trials of a word list
will be administered), and stimulus response mapping
(e.g., use of a response pad in an N back test). Some task fa-
miliarity effects may be due to procedural learning, an aspect
of cognition that remains relatively uncompromised in AD
[6]. Even if the active treatment outperforms the placebo
when both arms show practice effects, this effect may be
due to an enhancement of procedural memory, which will
not generate substantial benefit to the everyday cognitive
function of patients with AD [7]. The second component
can be termed practice-related effects. These include gains
made over multiple exposures to the test because of familiar-
ity with specific items (e.g., words on a list, a story to be re-
called). Developing strategies over time that alter
performance (e.g., clustering words semantically on a verbal
list-learning test) might occur either as a task familiarity
phenomenon or as a practice-related phenomenon. The
distinction between these two components is important
beyond nomenclature because it directly suggests different
trial design and test construction strategies for their reduc-
tion (see Sections 3 and 7 below). If not managed, these
practice effects could result in improvements that are
unrelated to valid drug-placebo differences in a clinical trial.
In the context of learning and memory, practice effects
would not be valid indices of specific cognitive enhancement
if they do not generalize or transfer readily to other tasks or
real-world activities that draw on ostensibly similar cogni-
tive operations [8]. This is often referred to as the “transfer
of training” problem. Thus, practice effects that do not relate
to concurrent improvements in broad domains of cognition
may be viewed as item or paradigm specific. They may
also engage different cognitive operations and neural sys-
tems (e.g., procedural learning) than those thought to be
treated in the intervention [9]. Also, some studies have
shown that improvements in performance with repeated
exposure can be used as prognostic indicators, including
those related to MCI to AD conversion [10] and survival
[11,12]. However, detailed discussion of these is outside
the scope of the present article, which focuses on the
adverse impacts of practice effects on clinical trial
outcomes. Rather, in the context of a clinical trial we will
cover in detail the interpretative and statistical problems
associated with practice effects (see especially Sections
5.4 and 7).
We begin with a selective review of the literature on prac-
tice effects in AD, MCI, and older healthy controls as they
relate to trials. We then present an example of how practice
effects were confounded with treatment effects from the
schizophrenia literature. Based on the literature and the
schizophrenia studies, which strongly suggest that practice
effects are present and large enough to obscure or be
mistaken for a treatment signal, we first discuss an array of
possible solutions. Next, we make recommendations for
managing practice effects in preclinical AD trials based
both on our review and experience in the psychometrics of
test construction. It is important from the outset to recognize
that our purpose is not to review the practice effect literature
comprehensively. This has already been done [10,13].
Rather, our purpose is to draw out the confounding
implications of practice effects in clinical trials in non–
cognitively impaired older populations and suggest
concrete remedies.
2. Methods
We first selectively review the literature in MCI and AD
with the intention of demonstrating that even in presump-
tively amnestic subjects, practice effects can be identified
in some cohorts. Our review in the AD and MCI groups is
not meant to be exhaustive or comprehensive but rather to
suggest that such effects are plausible occurrences. We
then shift our focus to older, cognitively healthy individuals
to demonstrate that such effects are common and measure-
able in serial assessment paradigms and to determine the
approximate magnitude of practice effects on cognitive tests
in this group. This latter group will be the focus of intense
interest as the AD field moves toward secondary prevention
trials in the preclinical AD spectrum.
3. Results
3.1. AD and MCI samples
Practice effects in AD have not been discussed often.
Perhaps, this is the result of an expectation that many patients
are substantially amnestic and unable to learn and consoli-
date item-level information over repeated testing. However,
memory impairments are dependent on individual differ-
ences in premorbid ability and disease stage, thus creating
some variability in training. Furthermore, impairments in
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other domainsmay not be as severe as those in neural systems
associated with the primary amnestic symptoms (hippocam-
pal and medial temporal lobe pathology) and so may also in-
crease the likelihood of practice effects (e.g., some learning
may engage striatal procedural learning systems that may
be relatively intact in AD). However, we acknowledge that
practice effects in AD and MCI are smaller than those in
healthier populations, and their significance perhaps argu-
able. At the same time, it should at least be considered that
practice effects could serve to obscure ongoing cognitive def-
icits in progressive degenerative dementia.
Even with these caveats, practice effects were observed
and commented on in early clinical trials of tacrine in AD
[14]. Practice effects on the Mini-Mental State Examination
were discernible using repeated-measures statistical tech-
niques in AD [15]. Indirect evidence for practice effects in
AD patients comes from the large number of cholinesterase
inhibitor clinical trials in which both the drug and placebo
groups demonstrated improvements in performance-based
outcomes measures early in the trial (in the 3- to 6-month
period) [16–18] with maximum effect sizes (ESs) in the
0.10 to 0.15 range. In contrast, practice effects in
Alzheimer’s Disease Neuroimaging Initiative’s (ADNI)
AD subjects, tested at 6 monthly intervals over the first
2 years, were negligible.
In ADNI’s MCI group, practice effects were evident for
logical memory, immediate and delayed recall, at 12 months,
but were small for most other measures (T.E.G., unpublished
data, 2014). In a clinical trial of MCI subjects that examined
the effect of two treatments, both generally deemed ineffective
(placebo and vitamin E), gains in multiple nonmemory do-
mains (e.g., language [semantic fluency and naming], execu-
tive [digits backward, digit symbol, number cancellation],
and visual processing [clock drawing]) were observed at 6
and 12 months [19]. ES gains ranged from about 0.06 to
0.30 in these domains. It is possible that these practice effects
reduced the ability of the measures to detect disease-related
declines in placebo groups and masked treatment effects.
In sum, practice effects can be identified in studies
involving MCI and AD subjects. The magnitude of practice
effects can vary across cohorts, and the literature is unclear
in identifying those tests that might be most sensitive or
insensitive to practice effects. Additionally, the magnitude
of such practice effects (when present) diminishes as the trial
progresses, and by the end of the trial, disease progression
often eliminates these practice effects and decline can be
observed. However, even when decline is observed, this
may be an underestimate of the true decline in cognitive abil-
ities because of practice effects. Furthermore, performance
on the repeated measures at early time points beyond base-
line may be inflated in both treatment and placebo groups.
3.2. Older healthy individuals
Anumber of studies involving repeated cognitive testing in
healthy elderly groups in longitudinal studies or non–central
nervous system–related clinical trials have identified practice
effects both at short and longer between-test intervals [20–
23]. Several of these studies indicated that such effects were
large enough to reduce or eliminate age-related decline over
several years [24,25]. In ADNI, practice effects were noted
for older controls (mean age 5 75 years) on several tests
including those involving speed, logical memory, and
naming. The ESs of these increases listed in Table 1 were in
the low to medium range (0.20–0.30). Findings from ADNI
may be especially important because they use several of the
tests likely to be used in preclinical AD trials, and the subjects
are likely to be representative of potential participants in pre-
clinical AD trials.
We next focus on two very recent studies that provide
further quantitative support for this view. The first is a
meta-analysis of practice effects and the second is a recent
and large study of practice effects (not included in the meta-
analysis). With respect to the former, Calamia et al. [13] re-
ported a comprehensive meta-analysis in healthy controls
and various neuropsychiatric groups that examined domain-
specific effects as well as composite effects and accounted
for various modifying factors, including age, test-retest inter-
val, and test domain. For any given test, the number of studies
ranged from 8 to 143 and from 12 subjects to 186. Calamia
et al. determined a composite practice effect of z (regression
weight) 5 0.24 in a modal middle-aged subject retested at a
1-year interval. In a well-conducted study using the Mayo
Clinic neurocognitive battery, Machulda et al. [26] found an
ES of 0.24 for their global composite in a sample of 947 cogni-
tively stable individuals (mean age, 78 years) whowere tested
three times over a 30-month period (and five times over 60
months). Improvements were largest in the learning and mem-
ory and smallest in language tests. Attention and speed mea-
sure gains fell between the two aforementioned domains.
Based on the moderator regression weights for age and retest
interval provided in the report by Calamia et al, as well as our
own experience [1,2] and that of others [26] with multiple re-
assessments (in which magnitude of improvement with a third
assessment is approximately half that of the initial T0–T1 re-
assessment), we estimate a performance gain of approximately
0.25 in healthy individuals in the 70- to 75-year age range un-
dergoing three assessments within a 6- to 12-month period.
Table 1
Maximal practice effects in the ADNI healthy control group with test-retest
intervals of 6 months or 1 year
Years Effect size
Trails A 0.5, 1, 2 0.22–0.31
DSST 1, 2 0.19–0.20
Boston Naming Test 0.5, 1, 2, 3, 5 0.31–0.48
Rey AVLT delayed 1, 2 0.20–0.31
Logical immediate 1, 2, 3, 4, 5, 6 0.43–0.72
Logical delayed 1, 2, 3, 4, 5, 6 0.25–0.53
Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative;
AVLT, Auditory Verbal Learning Test; DSST, Digit Symbol Substitution
Test.
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Although the sum total of improvement seems quite small, in
cases who are at risk for development ofMCI or dementia, this
amount of improvement could mask several years’ subtle
decline in cognition.
Practice effects may not be restricted to cognitive mea-
sures. Harvey et al. [27] demonstrated substantial practice
effects on the part of older (mean age 5 68 years) healthy
controls in the ability to perform tests of functional skills
when assessed at 18-month retest intervals. These individ-
uals were tested up to three times with a single form of a
performance-based functional capacity measure.
3.3. Schizophrenia clinical trials
Before discussing how practice effects may make inter-
pretation of clinical trial results challenging, we address
germane findings from schizophrenia antipsychotic trials
to anchor our interpretation of AD spectrum–related practice
effect findings to a concrete, nonhypothetical example of the
problems of separating practice effects from treatment ef-
fects. We first identified practice effects as a largely unrecog-
nized but pervasive problem in a clinical trial involving
putative cognitive-enhancing antipsychotic drugs in first-
episode subjects with schizophrenia and a healthy control
group [1]. Both groups were serially assessed at three time
points in a 16-week period with a comprehensive set of neu-
rocognitive measures. Both groups improved over time and
to a similar degree with an ES of 0.35 from T0 to T2. As the
healthy control group’s improvement could only be attrib-
uted to practice (based on item familiarity, given that alter-
nate forms were not used in the testing battery),
schizophrenia-related improvement of the same magnitude
could most parsimoniously be attributed to practice as
well. Furthermore, it is important to appreciate that although
schizophrenia subjects have widespread cognitive impair-
ments in the mild to moderate range, these did not preclude
the group from demonstrating a practice effect. Such prac-
tice effects have since been observed in multiple studies,
and it is now clear that practice effects are the best explana-
tion for improvement in several large trials in which patients
were randomized to second-generation antipsychotic drugs
or to a first-generation antipsychotic comparator and
assessed at multiple time points (e.g., [28,29]). Thus, there
is substantial evidence that the influences of these practice
effects had unfortunate consequences, as a confusing state
evolved with claims and counterclaims made for the
“benefits” of one antipsychotic or another.
4. Discussion
It is our hope that by drawing attention to this issue, the
field will begin to develop novel strategies that may over-
come changes in cognitive performance that are solely due
to practice effects. An organized attempt to reduce practice
effects will not only eliminate a large source of noise in
AD trials but also reduce the likelihood of misinterpreting
outcomes. As such, we believe that this issue should be dealt
with proactively in the design of clinical trials.
Critically, given our review of the literature, it is likely
that individuals who are at high risk for AD (symptomatic
or asymptomatic) and who are enrolled in trials and have
intact cognition or subtly impaired cognition will demon-
strate robust practice effects on many of the tests used. If
not controlled, these practice effects may mask subtle
decline in a placebo group, reducing the ability to detect im-
provements, if any, in the active treatment group. In this
latter group, conservatively, an ES of 0.25 units would likely
be larger than decline over a 6- to12-month period. Alterna-
tively, effects might be misinterpreted as active drug effects
in trials in which cohort differences in learning were present
and positive drug effects would have to be substantial to be
detected (see below).
5. Solutions
Several solutions to the problem of practice effects can be
considered (Table 2).
5.1. Use of alternate forms
On the face of it, the use of alternate forms would seem to
be a straightforward approach [30]. However, some tests
with problem-solving components (e.g., the Wisconsin
Card Sorting Test and similar procedures) and that require
discovery of an overarching and discrete set of rules are
Table 2
Rules of thumb for addressing practice effects in clinical trials
Approach Advantages Pitfalls
Use of a control group Necessary in placebo-controlled randomized clinical trial Prone to confounding a practice effect with a treatment effect
Massed practice (multiple
prebaseline testing)
Repeated testing during a prebaseline period may result in a
task familiarity–based asymptote and can reduce
interindividual and intraindividual variance due to
subjects not fully understanding task demands.
Differential asymptotes between tests; possible ceiling
effects; occlusion of treatment effects
Reliable change index Is rigorous Applicable to cases, not group means
Alternate forms Clearly reduce practice effects Forms may not be equivalent in difficulty level; influence of
strategy formation
Practice-insensitive tests Interpretation of improvement or lack of decline is
straightforward
Relevance of cognitive operations; sensitivity to treatment
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not easily amenable to this solution. Second, in other
problem-solving tasks, generation of various strategies can
result in improved performance across testing, even with
alternate forms. Third, alternate forms may not be equiva-
lent: They are often quite different in difficulty. This was
recently demonstrated on the Auditory Verbal Learning
Test (AVLT) in the non–cognitively impaired sample from
the ADNI study in which two parallel versions, forms A
and B, were administered over 5 years. Form B was admin-
istered at 6 months and 3 years, and form A at 1, 2, 4, and
5 years. Compared with performance at the start of the study,
the two forms showed either declines or improvements [24].
Fig. 1 presents the data from which it can be seen that
compared with performance at the start of the study, version
B of this verbal list-learning test was associated with signif-
icantly reduced performance at 6 months and 3 years,
whereas version A showed improvements, which were sig-
nificant for both immediate and delayed recall at 2 years.
Studies in schizophrenia have also revealed significant dis-
crepancies across forms of common tests in repeated-
measures designs [31]. Thus, alternate forms pose a signifi-
cant problem in that the more testing points that there are, the
more alternate forms are required. When forms of different
difficulty are administered over time, the true course of func-
tioning becomes very challenging to discern. In many ways,
practice effect variance across single forms is a more easily
managed problem than alternate forms of variable difficulty.
5.2. Reliable change index
The reliable change index (RCI) is a rigorous approach
that yields information on the number of individual subjects
who demonstrate gains above and beyond practice. A confi-
dence interval identifies the extent to which an individual
subject would have to improve to demonstrate progress
beyond a practice effect beyond reasonable doubt. The
statistic is dependent on not only differences in means be-
tween time points but also the variance of the difference
and the practice effect for untreated cases [2,32]. This
statistic is critical for treatment development because it
allows for estimation of the magnitude of change that
exceeds the practice effect on a placebo-corrected basis
that excludes all non–treatment-related differences. Never-
theless, this is a conservative statistic that does not consider
the fact that for nearly every treatment, not all treated cases
respond. Thus, the number needed to treat must be crossed
with the RCI for the outcome measures to understand the
magnitude of a group response that would suggest a truly
responsive subgroup. A similar approach uses regression
models that take into account individual demographics and
initial level of performance to define an expected score
and a confidence interval. This approach may be more flex-
ible than the RCI approach [32]. Additionally, the informa-
tion output is based on the case count, not group mean
differences. Nevertheless, cases can be combined and con-
trasted across conditions, although we are not aware of
any phase 3 trial that has used either of these statistics.
5.3. Prebaseline massed practice
In this approach, an attempt is made to reach an asymp-
tote in task familiarity–driven gains during a lead-in or pre-
baseline period of the trial by administering tests multiple
times in a short period (e.g., two to three administrations
within a day). This approach has been advocated for many
years [33,34]. Although several studies [35,36] have
indicated that two to three practice trials before baseline
result in asymptotic performance, others [37] indicate a
mixed picture, with different tests demonstrating asymptotes
over different number of repetitions. The intent in using
massed practice is to minimize issues of comprehension of
instructions, strategy formation, and inefficient stimulus
Fig. 1. Change from year 0 data in the ADNI studies for the Rey Auditory Verbal Learning Test. Ascending values reflect improvements and descending im-
pairments. The two parallel forms (A and B) are clearly not of equivalent difficulty. Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; AVLT,
Auditory Verbal Learning Test; LS, Least Square.
T.E. Goldberg et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 103–111 107
response mapping due to lack of familiarity, as opposed to
practice-related effects such as item exposure–related gains.
One aspect of this approach thatmay be problematic if per-
formance is relatively high at baseline is that a ceiling effect
associated with practice could prevent further change due to
treatment. Another potential problem with this approach is
that, after baseline, an artifactual decline can result because
of the use of an alternate form of the test not used in the pre-
baseline period or possible loss of retention of task familiar-
ity–based knowledge of instructions, sequence, strategies,
and so on. Additionally, other work has suggested that prac-
tice may recruit, engage, or otherwise occlude the same or
opposing neural systems as those targeted by treatment and
interfere with connectivity, neurochemical, or plasticity-
related alterations specific to active treatment [38].
5.4. Control groups
We do not agree with the frequently made argument that
the use of a control group obviates practice effect issues
because the essential comparison in a clinical trial is between
groups at end point and not change over time. First, it is easier
to detect a change signal against a “flat,” no practice effect
background than against a noisier, practice effect-plus-
treatment effect background. In keeping with this view, it
has been demonstrated that a procognitive drug effect (e.g.,
amphetamine in schizophrenia and donepezil in AD patients)
was much more likely to be identified using tests that did not
show practice effects, rather than using domain-similar tests
that were prone to practice effects [3,39]. These findings
may have been the result of reductions in practice-
associated variance. Alternatively, repeated exposure to the
same stimulus reduced potential plasticity in the neural sys-
tem targeted by the drug, thereby obscuring any benefit of
the drug on cognitive function. Second, if time is explicitly
taken into account in repeated measures in the comparison
of groups in a trial [40], an ES of 0.20 to 0.30, corresponding
to a barely noticeable between-group effect for treatment,
would be added to a practice-effect ES of 0.25 in more intact
populations. Thus, the gain in the active treatment group
would have to be as high as 0.50 for a difference between
treatment groups to be detected (as a group! time interac-
tion). This is large and would require a seemingly improbably
efficacious compound, particularly in cases with MCI or de-
mentia. Nevertheless, we acknowledge that this is a statisti-
cally driven model, and there is neither positive nor
negative data that directly bear on it.
5.5. A priori development of tests that are not prone to
practice effects
Sensitivity to the issue of practice effects in the a priori
design of a variety of tests that assay multiple cognitive
domains offers several advantages: use of cognitive science
paradigms that minimize individual item recall and strategy
shifts that could differentially impact performance,
development of alternate forms from large item pools, and
comprehensive co-normed data for the battery versions.
Thus, a novel battery of tests was recently constructed that
used specific principles from the cognitive science literature
to substantially reduce practice effects: (1) multiple items, a
restricted set of stimuli that serve to induce interference,
and alternative and equivalent forms with different items
and sequences in tests of attention, working memory, and ex-
ecutive function and (2) for episodic memory, obligatory
common encoding of items (to reduce strategy changes). Pre-
liminary results in 29 healthy controls (age range, 20–
50 years) who were tested three times in 16 weeks suggested
reduced practice effects (for all tests below an ES 5 0.15),
robust psychometrics, and lack of ceiling and floor effects
(T.E.G., unpublished data). Several tests have also directly ad-
dressed practice effects (via alternate forms) and have been
used in AD-related clinical trials. These include, but are not
restricted, to the following: Repeatable Battery for the
Assessment of Neuropsychological Status [41], CogState
Battery (including the Groton Maze Learning Test) [42–44],
and the Cognitive Drug Research (CDR) System [45–48],
but their factor structure, the computational operations
demanded by particular tests, and their relationship to
everyday function have not always been fully delineated.
6. Recommendations
Three approaches to attenuating practice effects involve
(1) massed practice in a prebaseline period so that a task fa-
miliarity having to do with comprehension of instructions,
development of simple strategies, stimulus response map-
ping, and testing sequence is increased; (2) use of tests
with multiple similar items, standardized encoding, and so
on that capitalize on cognitive science principles that reduce
recall of individual items or protect against large strategy
shifts that might influence recall; and (3) well-matched alter-
nate forms to minimize item exposure. Each has different
strengths, pragmatic implications, and economic costs. Our
list of suggestions is included in Table 2.
A clinical trial using tests that are designed to avoid the
impact of practice-related effects would look very much
like current trials in which baseline assessment at T0 by
version A of the test was followed by three more assessments
(T1-version B, T2-version C, and T3-version D) over an 18-
month period. Administration of test versions would be
counterbalanced. For trials in which prebaseline test admin-
istration was used (i.e., “massed practice”) to reduce task fa-
miliarity effects, two to three assessments before baseline
might reduce these artifacts [9,10].
For example, for a task of paired associate learning for
which there is benefit in understanding the paradigm, two
prebaseline assessments (version X) could serve to increase
task familiarity, with another version (A) serving as baseline.
This would be followed by three more assessments
(T1-version B, T2-version C, and T3-version D). Of course,
ceiling effects would have to be considered and minimized if
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necessary. Strategy changes in digit span (e.g., “chunking”
items or covert rehearsal) or in visual search during Trail-
Making Part B (appreciating that a number or letter may
be “under” one’s hand) and using semantic clustering in
memory tests might also be stabilized in prebaseline admin-
istrations. It might not be possible, however, to estimate in
advance how many massed practice sessions are required
to eliminate the possibility of subsequent improvements.
This solution might be especially useful in populations
with more substantial baseline impairments such as MCI
or AD, where improvement to ceiling is less likely.
7. Final thoughts
Consider the following thought experiment. An outcome
of a prevention trial in preclinical AD suggests that a neuro-
degenerative cascade has been arrested. This effective
disease-modifying treatment would result in stability in
cognitive function or small improvements, insofar as the
neurodegenerative effects are reversed. The untreated group
would decline, albeit subtly. A sensitive set of tests assaying
important cognitive domains and resistant to practice effects
would accurately monitor this scenario. In contrast, using
tests subject to practice effects, both groups would improve,
inaccurately representing the drug’s efficacy, resulting in the
strong possibility that differential effects would be masked
as the within-group change would be much greater than
the between-group change, and resulting in a serious type
2 error. In other words, the cognitive signal would have
been misaligned with underlying neurobiological changes
associated with neurodegeneration (neural system compro-
mises) and rectifications thereof.We think that interpretation
would be parsimonious and accurate if a treatment-related
signal could be identified in a group that would otherwise
demonstrate measurable subtle decline across time points.
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RESEARCH IN CONTEXT
1. Systematic review: In this review, we selectively
examined literature on practice effects in serial
cognitive assessment in healthy elderly, preclinical
Alzheimer’s disease (AD), and AD.
2. Interpretation: Practice effects are frequently found
in preclinical AD and reliably observed in healthy
elderly individuals. Their effect size is estimated to
be moderate (Cohen’s d5.25). We further suggest
that individuals with preclinical AD, who by defini-
tion are normal or near-normal cognitively, will
demonstrate practice effects that are similar in
magnitude to those in the healthy elderly. We provide
scenarios by which such effects could easily cloud
interpretation of results in clinical trials, such that a
drug effect is confounded with a practice effect
and/or does not align with neurobiological processes,
including aging and neurodegeneration.
3. Future directions: Critically, we also offer a set of
concrete recommendations on how to manage prac-
tice effects in clinical trials utilizing multiple and
distinct approaches.
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